加载中
NASDAQHealthcareBiotechnology
最新数据
US$3.165
−US$0.065 · -2.01%
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
常规交易时段
US$3.165
−US$0.065 · -2.01%
盘中时间采用ET。市场数据可能有所延迟。
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
日内区间
当前US$3.165
52周区间
当前US$3.165
盘中时间采用ET。市场数据可能有所延迟。
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
日内区间
当前US$3.165
52周区间
当前US$3.165
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | — | — | 65.4万 USD | 165.7万 USD |
| 毛利 | — | — | — | 65.4万 USD | 165.7万 USD |
| 研究与开发 | 6379.7万 USD | 7409.1万 USD | 5313万 USD | 4916.2万 USD | 4512.1万 USD |
| 销售、一般及管理费用 | 4546万 USD | 3167.5万 USD | 1538.3万 USD | 1200.1万 USD | 717.3万 USD |
| 营业费用 | 1.09亿 USD | 1.06亿 USD | 6851.3万 USD | 6116.3万 USD | 5229.4万 USD |
| 利息收入 | 613万 USD | 755.6万 USD | 286.7万 USD | 132.5万 USD | 1.5万 USD |
| 利息支出 | 20.6万 USD | 11.4万 USD | 20.5万 USD | 9.1万 USD | — |
| 折旧和摊销 | 207.9万 USD | 200.2万 USD | 184.3万 USD | 114.5万 USD | 1.3万 USD |
| 营业利润 | −1.09亿 USD | −1.06亿 USD | −6851.3万 USD | −6050.9万 USD | −5063.7万 USD |
| 净利润 | −9996.1万 USD | −9833.3万 USD | −6639.4万 USD | −5927.7万 USD | −5062.2万 USD |
公司数据更新于 2026年10月12日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1111.53万0.00%2.3万亿 USD0.03%US$381.87-0.02%
iShares Russell 2000 ETFIWM604.35万0.01%787.4亿 USD0.19%US$278.73-0.08%
State Street SPDR S&P Biotech ETFXBI514.69万0.05%98.74亿 USD0.35%US$152.6-0.76%
Vanguard Extended Market ETFVXF357.49万0.00%954亿 USD0.05%US$234.53-0.20%
Vanguard Russell 2000 ETFVTWO194.32万0.01%180亿 USD0.06%US$112.59-0.07%
State Street SPDR S&P Kensho New Economies Composite ETFKOMP181.34万0.07%26.06亿 USD0.20%US$65.595-1.14%
iShares Biotechnology ETFIBB173.32万0.02%108.2亿 USD0.44%US$205.36-0.55%
Dimensional - US Small Cap ETFDFAS166.96万0.00%338.69亿 USD0.31%US$78.49+0.18%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOState Street SPDR S&P Kensho New Economies Composite ETFKOMPiShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
